Basel, Switzerland, May 5, 2008 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announces that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema.
